Tau aggregation driven by microtubule-associated protein tau (MAPT) mutations is central to frontotemporal dementia pathology, yet no disease-modifying therapies effectively target mutant tau. Here, we identify purpurin (PUR) and oleocanthal (OLC) as selective inhibitors of mutant tau aggregation using peptide models spanning the R2R3 interface. Biophysical and cellular assays demonstrated that both compounds more effectively inhibit the aggregation of mutant tau peptides compared to wild-type, with PUR preferentially targeting V287I and N279K variants, and OLC showing broader inhibitory activity. Surface plasmon resonance and docking analyses revealed more stable interactions and lower binding free energies with mutant tau, consistent with their enhanced inhibitory effects. Computational studies using monomeric and fibrillar tau structures supported the mutation-specific binding profiles of PUR and OLC. Atomic force microscopy and confocal imaging confirmed reduced fibril formation, while post-transduction treatment assays showed that both compounds significantly suppressed intracellular tau propagation. Additionally, OLC reduced tau phosphorylation and oligomerization in SY5Y-TauP301L-EGFP cells expressing mutant tau. These findings highlight the potential of PUR and OLC as structurally distinct, mutation-targeted inhibitors of tau aggregation and propagation, providing a rationale for their further development as candidate therapeutics for frontotemporal dementia.

Department of Biomedical Engineering Faculty of Electrical Engineering and Communication Brno University of Technology Brno Czech Republic

Department of Medical Biophysics Faculty of Medicine and Dentistry Palacký University Olomouc Olomouc Czech Republic

Institute of Molecular and Translational Medicine Czech Advanced Technologies and Research Institute Palacký University Olomouc Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Al Rihani SB, Darakjian LI, Kaddoumi A. Oleocanthal‐rich extra‐virgin olive oil restores the blood–brain barrier function through NLRP3 inflammasome inhibition simultaneously with autophagy induction in TgSwDI mice. ACS Chem Neurosci. 2019;10:3543–3554. PubMed PMC

Annadurai N, Malina L, Malohlava J, Hajdúch M, Das V. Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation. Biochimie. 2022;200:79–86. PubMed

Annadurai N, Malina L, Salmona M, Diomede L, Bastone A, Cagnotto A, et al. Antitumour drugs targeting tau R3 VQIVYK and Cys322 prevent seeding of endogenous tau aggregates by exogenous seeds. FEBS J. 2022;289:1929–1949. PubMed

Aoyagi H, Hasegawa M, Tamaoka A. Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild‐type tau. J Biol Chem. 2007;282:20309–20318. PubMed

Bloom GS. Amyloid‐β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505–508. PubMed

Chen D, Bali S, Singh R, Wosztyl A, Mullapudi V, Vaquer‐Alicea J, et al. FTD‐tau S320F mutation stabilizes local structure and allosterically promotes amyloid motif‐dependent aggregation. Nat Commun. 2023;14:1625. PubMed PMC

Chen D, Drombosky KW, Hou Z, Sari L, Kashmer OM, Ryder BD, et al. Tau local structure shields an amyloid‐forming motif and controls aggregation propensity. Nat Commun. 2019;10:2493. PubMed PMC

Cino EA, Choy W‐Y, Karttunen M. Comparison of secondary structure formation using 10 different force fields in microsecond molecular dynamics simulations. J Chem Theory Comput. 2012;8:2725–2740. PubMed PMC

DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, et al. Synaptic tau seeding precedes tau pathology in human Alzheimer's disease brain. Front Neurosci. 2018;12:267. PubMed PMC

DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9:eaag0481. PubMed PMC

Ekman S, Flower R, Mahler S, Gould A, Barnard RT, Hyland C, et al. In silico molecular dynamics of human glycophorin a (GPA) extracellular structure. Ann Blood. 2021;6:11.

Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem. 2006;49:6177–6196. PubMed

Gao Y‐L, Wang N, Sun F‐R, Cao X‐P, Zhang W, Yu J‐T. Tau in neurodegenerative disease. Ann Transl Med. 2018;6:175. PubMed PMC

Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand‐binding affinities. Expert Opin Drug Discovery. 2015;10:449–461. PubMed PMC

Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014;111:E4376. PubMed PMC

Hong M, Zhukareva V, Vogelsberg‐Ragaglia V, Wszolek Z, Reed L, Miller BI, et al. Mutation‐specific functional impairments in distinct tau isoforms of hereditary FTDP‐17. Science. 1998;282:1914–1917. PubMed

Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′‐splice‐site mutations in tau with the inherited dementia FTDP‐17. Nature. 1998;393:702–705. PubMed

Li W, Sperry JB, Crowe A, Trojanowski JQ, Smith AB, Lee VM‐Y. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem. 2009;110:1339–1351. PubMed PMC

Monteiro KLC, Mendonça T, de Aquino E, da Silva‐Júnior F. Natural compounds as inhibitors of aβ peptide and tau aggregation. CNS Neurol Disord Drug Targets. 2024;23:1234–1250. PubMed

Monti MC, Margarucci L, Riccio R, Casapullo A. Modulation of tau protein fibrillization by oleocanthal. J Nat Prod. 2012;75:1584–1588. PubMed

Monti MC, Margarucci L, Tosco A, Riccio R, Casapullo A. New insights on the interaction mechanism between tau protein and oleocanthal, an extra‐virgin olive‐oil bioactive component. Food Funct. 2011;2:423–428. PubMed

Pounot K, Piersson C, Goring AK, Rosu F, Gabelica V, Weik M, et al. Mutations in tau protein promote aggregation by favoring extended conformations. JACS Au. 2024;4:92–100. PubMed PMC

Schrödinger . Schrödinger Release 2025‐1: LigPrep. New York: Schrödinger, LLC; 2025a.

Schrödinger . Schrödinger Release 2025‐1: induced fit docking protocol; Glide. New York: Schrödinger, LLC, 2024; Prime, New York: Schrödinger, LLC; 2025b.

Schrödinger . Schrödinger Release 2025‐1: Glide. New York: Schrödinger, LLC; 2025c.

Schrödinger . Schrödinger Release 2025‐1: Desmond molecular dynamics system, D. E. Shaw Research, New York, 2024. Maestro‐Desmond interoperability tools. New York: Schrödinger, LLC; 2025d.

Schrödinger . Schrödinger Release 2025‐1: Protein Preparation Wizard; Epik. New York: Schrödinger, LLC; Impact. New York: Schrödinger, LLC; Prime. New York: Schrödinger, LLC; 2025e.

Seidler PM, Boyer DR, Murray KA, Yang TP, Bentzel M, Sawaya MR, et al. Structure‐based inhibitors halt prion‐like seeding by Alzheimer's disease‐ and tauopathy‐derived brain tissue samples. J Biol Chem. 2019;294:16451–16464. PubMed PMC

Soeda Y, Saito M, Maeda S, Ishida K, Nakamura A, Kojima S, et al. Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers: a plausible key to understanding failure of a clinical trial for Alzheimer's disease. J Alzheimer's Dis. 2019;68:1677–1686. PubMed

Soeda Y, Takashima A. New insights into drug discovery targeting tau protein. Front Mol Neurosci. 2020;13:590896. PubMed PMC

Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–622. PubMed

Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998;95:7737–7741. PubMed PMC

Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, et al. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four‐repeat human tau protein. Am J Pathol. 1999;155:2153–2165. PubMed PMC

Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Investig. 2019;99:912–928. PubMed PMC

Sun KT, Patel T, Kang S‐G, Yarahmady A, Srinivasan M, Julien O, et al. Disease‐associated mutations in tau encode for changes in aggregate structure conformation. ACS Chem Nerosci. 2023;14:4282–4297. PubMed PMC

Viswanathan GK, Shwartz D, Losev Y, Arad E, Shemesh C, Pichinuk E, et al. Purpurin modulates tau‐derived VQIVYK fibrillization and ameliorates Alzheimer's disease‐like symptoms in animal model. Cell Mol Life Sci. 2020;77:2795–2813. PubMed PMC

von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow E‐M, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local β‐structure. J Biol Chem. 2001;276:48165–48174. PubMed

Wang X, Friesen E, Müller I, Lemieux M, Dukart R, Maia IB, et al. Rapid generation of human neuronal cell models enabling inducible expression of proteins‐of‐interest for functional studies. Bio Protoc. 2020;10:e3615. PubMed PMC

Xia Y, Sorrentino ZA, Kim JD, Strang KH, Riffe CJ, Giasson BI. Impaired tau–microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations. J Biol Chem. 2019;294:18488–18503. PubMed PMC

Yao Q‐Q, Hong L, Wu S, Perrett S. Distinct microscopic mechanisms for the accelerated aggregation of pathogenic tau mutants revealed by kinetic analysis. Phys Chem Chem Phys. 2020;22:7241–7249. PubMed

Yao T‐M, Tomoo K, Ishida T, Hasegawa H, Sasaki M, Taniguchi T. Aggregation analysis of the microtubule binding domain in tau protein by spectroscopic methods. J Biochem. 2003;134:91–99. PubMed

Young AL, Bocchetta M, Russell LL, Convery RS, Peakman G, Todd E, et al. Characterizing the clinical features and atrophy patterns of MAPT‐related frontotemporal dementia with disease progression modeling. Neurology. 2021;97:e941–e952. PubMed PMC

Zhu L, Qian Z. Recent studies of atomic‐resolution structures of tau protein and structure‐based inhibitors. Quant Biol. 2022;10:17–34.